Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Authors
Cummings, JeffreyZweifel, M
Smith, N
Ross, P
Peters, J
Rustin, G
Price, Patricia M
Middleton, M R
Ward, Timothy H
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Manchester Cancer Research Centre, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. jcummings@picr.man.ac.ukIssue Date
2012-05-22
Metadata
Show full item recordAbstract
OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h.Citation
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. 2012, 106 (11):1766-71 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2012.165PubMed ID
22538971Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2012.165